or Try an Advanced Search...

    Technical Analysis for ACHL - Achilles Therapeutics plc

    Grade Last Price % Change Price Change
    F 0.92 11.25% 0.09
    ACHL closed up 11.25 percent on Wednesday, May 8, 2024, on 1.53 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Up
    Historical ACHL trend table...
    Date Alert Name Type % Chg
    New Uptrend Bullish 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Stochastic Reached Overbought Strength 0.00%
    Earnings Movers Other 0.00%
    Weak + Overbought Other 0.00%
    Above Upper BB Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Boomer Sell Setup Bearish Swing Setup 11.25%
    1,2,3 Retracement Bearish Bearish Swing Setup 10.74%
    Older End-of-Day Signals for ACHL ...

       Recent Intraday Alerts

    Alert Time
    Up 10% about 8 hours ago
    60 Minute Opening Range Breakout about 10 hours ago
    Possible Pocket Pivot about 10 hours ago
    Up 1 ATR about 10 hours ago
    Upper Bollinger Band Resistance about 12 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ACHL Chart by TradingView
    Basic chart:

    Profile

    Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Clinical Medicine Solid Tumors Cancer Treatment Cancer Immunotherapy Melanoma Antineoplastic Drugs Orphan Drug Breakthrough Therapy Bladder Cancer Head And Neck Cancer Renal Cell Carcinoma Advanced Non Small Cell Lung Cancer Head And Neck Squamous Cell Carcinoma Immuno Oncology Biopharmaceutical Triple Negative Breast Cancer

    Is ACHL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 5 Piper downgrades Achilles to neutral, cites latest data
    Apr 4 Achilles Therapeutics GAAP EPS of -$0.46 misses by $0.32
    Apr 4 Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
    Apr 4 Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
    Feb 9 Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
    Feb 5 Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
    Jan 24 Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
    Dec 18 Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
    Nov 13 Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
    See more ACHL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.76
    52 Week Low 0.74
    Average Volume 373,260
    200-Day Moving Average 0.94
    50-Day Moving Average 1.03
    20-Day Moving Average 0.80
    10-Day Moving Average 0.80
    Average True Range 0.06
    RSI (14) 56.52
    ADX 29.64
    +DI 21.69
    -DI 14.85
    Chandelier Exit (Long, 3 ATRs) 0.74
    Chandelier Exit (Short, 3 ATRs) 0.93
    Upper Bollinger Bands 0.88
    Lower Bollinger Band 0.73
    Percent B (%b) 1.26
    BandWidth 19.08
    MACD Line -0.05
    MACD Signal Line -0.07
    MACD Histogram 0.026
    Fundamentals Value
    Market Cap 37.48 Million
    Num Shares 40.8 Million
    EPS -1.90
    Price-to-Earnings (P/E) Ratio -0.48
    Price-to-Sales 0.00
    Price-to-Book 0.25
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.08
    Resistance 3 (R3) 1.07 1.00 1.06
    Resistance 2 (R2) 1.00 0.96 1.01 1.05
    Resistance 1 (R1) 0.96 0.93 0.98 0.97 1.04
    Pivot Point 0.89 0.89 0.90 0.90 0.89
    Support 1 (S1) 0.85 0.85 0.87 0.86 0.80
    Support 2 (S2) 0.78 0.82 0.79 0.79
    Support 3 (S3) 0.74 0.78 0.78
    Support 4 (S4) 0.76